Figure 5

In vivo priming efficiency of MART-1-positive DC. (A) Specific lysis of mel624.38 (HLA-A2⁺, MART-1⁺) and THP-1 (HLA-A2⁺, MART-1^-) target cells by splenic-derived human lymphocytes isolated from mice vaccinated with various mDC types. Depicted are means of results from 16 mice total per group generated in 4 individual experiments and tested for significance using a two-tailed Mann-Whitney test (p values were considered as following * p < 0.05; ** p < 0.005; *** p < 0.0001) (B) Relative lysis of results shown in (A) adjusted for numbers of human CD8⁺ T cells. To account for individual experiments and mice, values were adjusted at an E:T of 20:1 as follows:% rel. specific lysis = % spec. lysis/(% CD8/100). Given are means with SEM (* p < 0.05; ** p < 0.005; *** p < 0.0001, assessed by a two-tailed Mann-Whitney test). (C) Percentage of responding mice after vaccination with MART-1-expressing mDC of an HLA-A2⁺ donor. Mice were considered as responders when human lymphocytes, isolated and cultured from spleens, showed a specific lysis of HLA-A2⁺, MART-1⁺ target cells (mel624.38) higher than 20% at an E:T of 40:1. Analyzed were 4 individual experiments with a total of 16 mice in each group.